Bioheng Announced Oral Presentation of Its Preliminary Results of CRISPR-Engineered Allogeneic CAR-T for r/r B-ALL Treatment at 2020 ASH Meeting

HANGZHOU and NANJING,China,Nov. 10,2020 -- Bioheng Biotech Co.,Ltd,a clinical-stage biotechnology company focuses on developing novel cellular immunotherapy,today announced that their preliminary data including the pre-clinical development,manufacturing,and investigator initiated trial (IIT) results for CTA101,a CRISPR/Cas9-engineered off-the-shelf CD19/CD22 dual-targeted CAR-T cell product,will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually on December 5-8,2020. The study was designed to evaluate the feasibility of CTA101 in patients with relapsed/refractory B-cell acute Lymphoblastic Leukemia (r/r B-ALL).

"CTA101,a CRISPR-engineered allogeneic dual-targeted CAR-T,has showed manageable safety and promising efficacy in the treatment of r/r B-ALL patients," said the PI of this study,He Huang,MD,PhD,Professor of hematology,President of The First Affiliated Hospital,Zhejiang University School of Medicine. "It has preliminarily verified the feasibility of generating allogeneic CAR-T by CRISPR gene editing and provided evidence for extended application in the future. As an allogeneic CAR-T,CTA101 tackles several limitations associated with conventional CAR-T therapy,such as possible manufacturing failures,undesirable waiting period between leukapheresis and CAR-T infusion,poor product consistency due to bespoke manufacturing process for individual patient,and unaffordable cost. In addition,its dual-targeted design may be a viable solution to reduce the relapse rate of B-ALL. I would like to expect more allogeneic CAR T cell products for clinical use,which certainly provide more choices to address the unmet medical needs."

Oral Presentation

Title: 499 The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Session: 801. Gene Editing,Therapy and Transfer I

Date: Sunday,December 6,2020

Time: 2:30 p.m. ET (11:30 a.m. PT)

https://ash.confex.com/ash/2020/webprogram/Paper142262.html

"We are looking forward to sharing initial data on the feasibility,safety and efficacy of our first allogeneic CAR T cell product,CTA101,at the ASH 2020 annual meeting," said Xiaohong He,CEO of Bioheng Biotech. "CTA101 is based on our first-generation allogeneic CAR T technology platform,which can be timely infused to patients without HLA matching. Bioheng has always been committed to the development and commercialization of allogeneic CAR-T cell technologies and products. The positive results of CTA101 will further promote the development and translation of our multiple allogeneic CAR T pipelines."

About Bioheng

Bioheng is a leading clinical-stage biotech company focusing on the development of novel allogeneic cellular immunotherapy for immediate treatment of patients with hematologic and solid tumors. Allogeneic CAR-T may significantly increase the affordability and accessibility through overcome the obstacles encountered by autologous CAR-T. Currently,Bioheng has established a pioneering allogenic immunotherapy platform and built a 55,000 square feet high standard GMP-level R&D and translational center. https://www.bioheng.com/en/index.php/welcome.html

View original content:/news-releases/bioheng-announced-oral-presentation-of-its-preliminary-results-of-crispr-engineered-allogeneic-car-t-for-rr-b-all-treatment-at-2020-ash-meeting-301169918.html